Workflow
Tim Nicholls appointed EVP
icon
Search documents
“中国药谷”领航生命健康“兴”力量
Core Viewpoint - The Daxing Biomedical Industry Base, known as "China Pharmaceutical Valley," is accelerating its development in the life and health industry, aiming for high-quality growth and international influence by 2025 [1][3][13]. Group 1: Industry Development - The life and health industry is a strategic emerging industry crucial for national security and public welfare, with Daxing District being a key area for its development in Beijing [3][4]. - The Daxing Biomedical Industry Base has expanded by 9.1 square kilometers, enhancing its capacity for industrial research and production, as well as supporting services [4]. - The base is set to strengthen its core industries, including vaccines, traditional Chinese medicine, and high-end medical devices, while also exploring new sectors like medical aesthetics and animal pharmaceuticals [7][13]. Group 2: Project Initiatives - Several high-impact biomedical projects are set to be established in the Daxing Biomedical Industry Base, including innovative drug development and antibody production [6]. - The second phase of the China Food and Drug Inspection Institute's project has commenced, significantly boosting the region's research and testing capabilities [5]. - The base is actively promoting the construction of a new campus for Capital Medical University, which will enhance research innovation and industry integration [4]. Group 3: Technological Integration - The Daxing Biomedical Industry Base is leveraging big data and artificial intelligence to enhance its service and digital capabilities across various sectors [8][10]. - The base is transitioning from a product-oriented approach to a service-oriented model, exemplified by the establishment of a new retail consumption model by Tongrentang Health [8]. - Advanced AI technologies are being integrated into drug research and development, marking a significant shift towards innovative pharmaceutical solutions [10]. Group 4: Policy and Support - The Daxing Biomedical Industry Base is implementing a "one-stop service platform" to optimize the business environment and support enterprises in accessing various policy benefits [12]. - The base has facilitated the application of over 50 projects for national and municipal policy support, enhancing the operational capabilities of more than 30 enterprises [12]. - The base is committed to fostering a collaborative ecosystem by establishing shared platforms for high-value instruments and equipment among research institutions [11].
港股午评:恒生指数跌0.48% 港股在线旅游股午前飙涨
news flash· 2025-06-26 04:03
港股午间收盘,恒生指数跌0.48%,恒生科技指数收平。港股在线旅游、酒店餐饮与休闲股午前飙涨, 香港中旅涨超61%,海昌海洋公园涨近20%,专业旅运涨超13%。港股券商股继续活跃,胜利证券大涨 超127%,中国光大控股涨超28%。 ...
国家发展改革委政策研究室副主任李超:初步预计今年迎峰度夏期间全国最高用电负荷同比增加约1亿千瓦
news flash· 2025-06-26 04:03
国家发展改革委政策研究室副主任李超26日在国家发展改革委6月份新闻发布会上表示,近期局部地区 频繁出现高温天气,有网友评论"都快热化了",各家各户的空调都在连轴转。一般来讲,夏季是全年用 电负荷高峰,能源保供关键在"电",初步预计,今年迎峰度夏期间全国最高用电负荷同比增加约1亿千 瓦。 ...
亚朵开始降价,想稳住加盟商
Sou Hu Cai Jing· 2025-06-26 04:03
作者 | 源Sight 王言 酒店行业价格战仍未停歇,为了增强加盟商信心,亚朵似乎在主动为其"减负"。 近日,归属于上海亚朵商业管理(集团)有限公司的微信公众号"几木里"发文称,为了更好地赋能合伙人经营,亚朵供应链聚焦成本优化与 品质提升,推出一系列务实举措,为合伙人经营实效加码。 来源:几木里微信公众号 总的来说,亚朵将通过供应链降本的方法,下调部分酒店用品和工程物资价格,可以压低加盟商的经营成本。不过,如何在降低成本的同时 确保产品品质,同时与供应链条实现共赢,也是亚朵需要考虑的问题。 上游降本 过去很长一段时间,酒店行业供应链体系中,一直存在效率、成本与体验之间的矛盾。 次方点评CHPI《中国酒店产业供应链指数》报告显示,整个行业供应链个别品类价格偏高约10%,日常运营物资约90%从平台采购,但是缺 乏价格优势,物流配送速度乏力。 源Sight注意到,亚朵此次成本优化与品质提升举措包括多个方面:1、高频运营物资大幅降价,继拖鞋、房卡套等,高频运营物资降价后, 6月30日起,"奉茶纸杯"将降价51.8%,"懒人抹布"同步下调10.2%; 2、工程物资,协同降本,窗帘、装配板、墙纸墙布等关键工程物资价格优化 ...
小红书运营工作模型
Sou Hu Cai Jing· 2025-06-26 03:56
Core Insights - The report outlines the operational model of Xiaohongshu, covering various aspects such as topic selection, title writing, content modeling, cover design, trend tracking, and traffic operation [1] Topic Selection Strategy - The topic selection follows a four-step method: "Find, Select, Combine, and Change." "Find" involves gathering topics through various channels like recommendations, searches, and social media, while also considering personal experiences and trending keywords. "Select" filters topics based on relevance and novelty. "Combine" integrates topics with personal experiences using ten methods for determining writing angles. "Change" involves continuous iteration of topics based on data analysis of user needs [2] Title Writing - Titles are crucial for content dissemination, accounting for 30% of its value. Effective titles should quickly convey the content, spark curiosity, and meet social sharing needs. Writing should adhere to six principles of clarity and simplicity, utilizing various techniques such as question formats and trending topics [3] Content and Cover Model - Content structure can be built using models like 3W1H and AIDA. The 3W1H model focuses on the "why" and "who" aspects, while AIDA is used to attract attention and generate interest. Cover design should prioritize concise text (not exceeding 20 words) and impactful visuals, with common structures including contrast and comparison. Note dimensions should adhere to a 3:4 standard to avoid cropping [4] Trend and Traffic Operation - When pursuing trends, it is essential to maintain ethical boundaries, focusing on occasional trends rather than government policies. In traffic operations, the discovery page accounts for 70% to 80% of traffic, with recommendations based on user preferences. Establishing a topic library and emphasizing title and cover design are critical for effective operations [5]
6月游戏版号数量创今年新高,传媒ETF(159805)红盘上扬
Xin Lang Cai Jing· 2025-06-26 03:55
传媒ETF紧密跟踪中证传媒指数,中证传媒指数从营销与广告、文化娱乐、数字媒体等行业中,选取总 市值较大的50只上市公司证券作为指数样本,以反映传媒领域代表性上市公司证券的整体表现。 数据显示,截至2025年5月30日,中证传媒指数(399971)前十大权重股分别为分众传媒(002027)、岩山科 技(002195)、昆仑万维(300418)、恺英网络(002517)、光线传媒(300251)、利欧股份(002131)、三七互娱 (002555)、蓝色光标(300058)、神州泰岳(300002)、巨人网络(002558),前十大权重股合计占比48.11%。 6月24日晚,国家新闻出版署发布了6月份的国产和进口网络游戏审批信息。本次国产版号数量为147 个,进口网络游戏版号有11款,本批次版号数量创今年新高。 万联证券表示,从2025年Q1SW传媒行业的基金重仓配置及估值水平看,估值水平明显有所修复,行业 整体仍处于低配区间,存在较大提升空间,游戏及广告营销领域头部公司是机构关注的核心,建议关注 游戏版号储备丰富、布局AI应用的游戏公司,数字营销及梯媒领域龙头公司。 截至2025年6月26日 11:11,中证传 ...
买房要避免4楼、14楼、18楼?内行人:这四个楼层更不建议购买
Sou Hu Cai Jing· 2025-06-26 03:55
国内房价高企,购房者往往倾尽积蓄,背负数十年房贷,才能勉强拥有一个住所。买房,无疑是人生中最重 大的一次消费决策,因此购房者对地段、户型、朝向、楼层等细节都异常关注。坊间流传着关于楼层"风水"的 说法,其中4楼、14楼、18楼尤为忌讳,谐音或意象与不祥之兆相关联,例如"4"和"14"谐音"死",而"18"则 与"十八层地狱"联系在一起。但业内人士认为,这些楼层本身并不会影响居住体验,然而,部分楼层的确存在 一些实际问题,可能影响居住生活质量。让我们逐一分析: 四、一楼(无花园): 一楼方便出行,无需乘坐电梯,对于老年人而言较为友好。然而,其劣势同样不容忽 视。首先,通风采光差,阳光难以直射,室内昏暗潮湿,需要长时间开灯。其次,地面噪音、蚊虫滋扰、隐 私泄露以及防盗问题都让一楼住户倍感困扰。夏天,为了防止蚊虫入侵和噪音干扰,几乎无法开窗,私密性 也较差。此外,一楼地面的潮湿也导致地板需要频繁更换,增加额外支出和维护成本。 二、二楼: 二楼的劣势与一楼相似,采光通风欠佳,同样面临防盗、噪音(尤其来自地面)、蚊虫困扰等问 题。更令人头疼的是,二楼更容易遭遇下水管道反水,尤其在夏季,厕所和盥洗室的反水现象更加严重,异 ...
6月26日早间重要公告一览
Xi Niu Cai Jing· 2025-06-26 03:55
Group 1 - Changchuan Technology expects a net profit of 360 million to 420 million yuan for the first half of 2025, representing a year-on-year increase of 67.54% to 95.46% [1] - The expected non-operating income for the reporting period is approximately 70 million yuan, mainly influenced by mergers and acquisitions and government subsidies [1] - Changchuan Technology specializes in the research, production, and sales of integrated circuit equipment [1] Group 2 - Lianhua Holdings' subsidiary plans to sell four intelligent computing servers for a total of 4.2 million yuan [1] - Lianhua Holdings is involved in the production and sales of various food products, including monosodium glutamate and chicken essence [1] Group 3 - Lutai A has generated a profit of 81.04 million yuan from the sale of Rongchang Biological shares, which accounts for over 10% of its audited net profit for the last fiscal year [1][2] - Lutai A focuses on the production and sales of high-end shirt fabrics and garments [2] Group 4 - Hejing Bio's shareholder plans to reduce their stake by up to 1.94%, equating to 180,000 shares [2] - Hejing Bio operates in the medical device sector, specifically in in vitro diagnostics [2] Group 5 - Guoxuan High-Tech announced that its solid-state battery technologies have not yet achieved commercial application [2] - The company is currently in the pilot production phase for its second-generation solid-state batteries and has begun customer testing [2] - Guoxuan High-Tech specializes in the research, production, and sales of power battery systems and energy storage systems [3] Group 6 - Wangsong Technology's major shareholder plans to reduce their stake by up to 0.5%, which is approximately 12.22 million shares [4] - Wangsong Technology is engaged in CDN and edge computing services, as well as cloud security [4] Group 7 - Teda Co. plans to repurchase shares worth between 35 million and 70 million yuan, with a maximum price of 5.89 yuan per share [4] - Teda Co. is involved in ecological environmental protection and regional development [4] Group 8 - Jialian Technology intends to acquire a 51% stake in Hongxiang Runfeng for 11.20 million yuan to support its overseas business strategy [4][5] - Jialian Technology focuses on the development and production of biodegradable products [5] Group 9 - Alloy Investment is in the process of a potential change in control, with its stock continuing to be suspended [5] - Alloy Investment specializes in the production and sales of nickel-based alloy materials [5][6] Group 10 - Oumei Medical's shareholder plans to reduce their stake by up to 3%, which is approximately 18.56 million shares [6] - Oumei Medical is involved in the production of medical consumables and protective products [6] Group 11 - Tianyu Co. plans to reduce its shares by up to 3%, with a total of 1.00% of its shares being sold [7][8] - Tianyu Co. specializes in the research and production of intermediates and raw materials for pharmaceuticals [8] Group 12 - Century Hengtong's board members plan to reduce their stakes by a total of 0.42% of the company's shares [8] - Century Hengtong provides value-added services to large enterprises in various sectors [8] Group 13 - Construction Bank plans to issue 11.589 billion shares to raise 105 billion yuan [10] - Construction Bank is involved in banking and financial services [11] Group 14 - Zhongda An is planning a change in control and will resume trading after issuing shares to a specific entity [12] - Zhongda An focuses on construction project management and consulting services [12] Group 15 - Mengjie Co. plans to reduce its shares by up to 0.27%, which is approximately 200,000 shares [13] - Mengjie Co. specializes in high-end bedding products [13] Group 16 - Lianlong plans to reduce its stake by up to 3%, equating to approximately 688,860 shares [14] - Lianlong is involved in high polymer materials and life sciences [14] Group 17 - Shenling Environment's shareholders plan to reduce their stakes by a total of 3% [15] - Shenling Environment provides environmental control solutions for various applications [15] Group 18 - Ximai Food's actual controller and associates plan to reduce their stakes by a total of 223,210 shares [16] - Ximai Food specializes in the research and production of oat-based food products [17] Group 19 - Jieqiang Equipment's actual controller has been detained for alleged bribery, which may impact the company's future development [18] - Jieqiang Equipment specializes in the production and sales of nuclear and biochemical safety equipment [18]
创新药大跌,有何原因?荣昌生物跌超15%,泰它西普BD首付款仅4500万美金!港股通创新药ETF(159570)跌超2%,1.36亿资金逢跌布局!
Xin Lang Cai Jing· 2025-06-26 03:53
今日港股集体回调,继四连涨后,港股通创新药ETF(159570)跌超2.5%,成交额快速突破13亿元!资金汹涌流入,港股通创新药ETF(159570)盘中净流入1.36 亿元,最新规模超75亿元强势领先同类,创上市以来新高! 消息面上,荣昌生物今早宣布,将公司具有自主知识产权的泰它西普有偿许可给美国纳斯达克上市公司Vor Bio,Vor Bio将获得泰它西普在除大中华区以外 的全球范围内开发、生产和商业化的独家权利;荣昌生物将取得Vor Bio价值1.25亿美元现金及认股权证(包括4500万美元的首付款和价值8000万美元的认股 权证,认股权证可以每股0.0001美元认购Vor Bio 3.2亿股的普通股,约占Vor Bio经扩大总发行股本的23%)、最高可达41.05亿美元的里程碑付款,总金额 42.3亿美元,此外荣昌生物还将收到高个位数至双位数销售提成款。 受消息影响,荣昌生物低开近15%,盘中一度跌超22%。值得关注的是,此前4个交易日荣昌生物累涨超34%。港股通创新药ETF(159570)标的指数其他成分 股也多数飘绿:信达生物跌近4%,据今晨公告,信达生物拟折价4.9%配售5500万股,预计净筹42 ...
8元啤酒混战起,珠江啤酒能否入场全国赛?
Xin Lang Cai Jing· 2025-06-26 03:53
文 | 酒讯 半颗 编辑 | 方圆 6月的一纸换帅公告,让珠江啤酒在夏日的舆论场燥热了起来。 执掌珠江啤酒十二年的董事长王志斌正式卸任,由前总经理黄文胜接棒。交接发生在一个微妙节点:过 去十年,王志斌为珠江啤酒打下了坚实的高端化基础,推动"3+N"品牌矩阵成型,97纯生更是将8元价 格带打造成新的业绩引擎。但另一边,全国化却迟迟未见突破,公司95%以上营收仍来自华南。 啤酒高端化战火正盛,8元价格带成为兵家必争之地。在这场日益激烈的战役中,新官上任的珠江啤酒 能否带着8元啤酒迎来新局面? | | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 5, 731, 079, 366. 33 | 5, 378, 040, 272. 06 | 6.56% | 4, 928, 137, 239. 13 | | 归属于上市公司股东 | 810, 273, 197. 13 | 623, 507, 931. 85 | 29.95% | 598, 264, 071. 35 | | 的净利润(元) | | | | | ...